Abstract:There is an acute unmet need to develop novel treatment regimens in the perioperative setting since many patients with muscle-invasive bladder cancer (MIBC) are not eligible for the current standard of care (SOC) neoadjuvant treatment with cisplatin-based chemotherapy. The introduction of immune checkpoint inhibitors (ICIs), both as monotherapy and in combination regimens with other ICIs, chemotherapy, or targeted drugs, may provide safe and clinically effective treatment options that could revolutionize current standard of care. In the neoadjuvant setting, compelling data from phase II clinical trials suggests that single-agent immunotherapy, as well as dual-checkpoint blockade, may emerge as reasonable alternatives to traditional cisplatin-based chemotherapy. Prospective studies combining ICIs with chemotherapy or with antibody-drug conjugates have also demonstrated robust outcomes. However, these studies are not yet practice changing and data from larger randomized studies are needed to confirm this benefit. In the adjuvant setting, nivolumab is the FDA-approved treatment based on a disease-free survival benefit relative to placebo in a randomized trial. However, it will be important to confirm an overall survival benefit of this treatment and to better identify patients who need additional adjuvant treatment based on novel biomarker data. The treatment of muscle-invasive bladder cancer is moving toward the individualization of treatment options based on specific tumor and patient characteristics and away from the one-size-fits-all approach that has dominated this space for the last couple of decades. Emerging biomarker data, such as with ctDNA, suggests that immunotherapy may confer greater benefit to selected patients. Identifying who those patients are will be of paramount importance since additional treatments always come with additional toxicities. On the other hand, the more favorable toxicity profiles of certain immunotherapy-based regimens may make them superior options for some patients who would otherwise be unable to tolerate other systemic regimens. In the near future, it is likely that subsets of patients with MIBC will be receiving treatments with predominantly immunotherapy-based regimens while many patients may still be treated with regimens containing a cisplatin-based chemotherapy backbone. Currently ongoing clinical trials will help to better define patient populations optimized for each treatment.

The evolving role of multidisciplinary teams in optimizing non-muscle invasive bladder cancer care

Management of Muscle-invasive Bladder Cancer in the 2020s: Challenges and Perspectives

Abstract IA012: Novel approaches to the management of non-muscle invasive bladder cancer

Advances in diagnosis and treatment of bladder cancer

Current Landscape and Future Directions on Bladder Sparing Approaches to Muscle-Invasive Bladder Cancer

Managing Patients with Non-Muscle Invasive Bladder Cancer: Old Disease, New Ideas

Recent advancements in the diagnosis and treatment of non-muscle invasive bladder cancer: Evidence update of surgical concept, risk stratification, and BCG-treated disease

New Perspectives in the Medical Treatment of Non-Muscle-Invasive Bladder Cancer: Immune Checkpoint Inhibitors and Beyond

A Role of Multimodality Bladder-Preserving Therapy in Patients with Muscle-Invasive Bladder Cancer Plus Hydronephrosis with or Without Pelvic Nodal Involvement.

Perioperative Immunotherapy in Muscle-Invasive Bladder Cancer

Non-muscle-invasive bladder cancer: An overview of potential new treatment options

Revolutionizing Treatment: Breakthrough Approaches for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer

Muscle invasive bladder cancer: where is the field headed?

Advancements in Urothelial Cancer Care: Optimizing Treatment for Your Patient

Treatment Modalities for Non-Muscle Invasive Bladder Cancer: An Updated Review

The Current Progress and Future Options of Multiple Therapy and Potential Biomarkers for Muscle-Invasive Bladder Cancer

Developments in conservative treatment for BCG-unresponsive non-muscle invasive bladder cancer

Factors Influencing Patient Decision-Making in the Treatment of Muscle-Invasive Bladder Cancer

Current and Future Landscape of Perioperative Treatment for Muscle-Invasive Bladder Cancer

Challenges and opportunities in NMIBC management across Latin America: insights from healthcare providers and a patient advocacy group

Bladder-sparing protocols in the treatment of muscle-invasive bladder cancer